FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282963013> ?p ?o ?g. }

• W4282963013 endingPage "2564" @default.
• W4282963013 startingPage "2564" @default.
• W4282963013 abstract "Abstract Lineage-specific transcriptional networks drive cellular differentiation and development. Disruption of these specific cell programs can result in cancer and create a subset of tumors that are “transcriptionally addicted.” Sarcomas, for example, are characterized by an oncogenic fusion protein consisting of a FET family RNA-binding protein fused to a transcription factor (TF). The oncogenic fusions result in a restructuring of the transcriptome promoting cancer. In chordoma, TBXT (brachyury)—normally involved in notochord differentiation—is aberrantly expressed, resulting in promotion of cancer. As these oncogenic TFs are difficult to target directly, we and others have proposed targeting associated transcriptional regulators to inhibit their activity. Cyclin-dependent kinase 9 (CDK9) interacts with TFs to promote activation of target genes and promotes transcription elongation through phosphorylation of RNA polymerase II. We have developed a potent, selective, and orally bioavailable CDK9 inhibitor, KB-0742. Here we present the preclinical activity of KB-0742 in models of sarcoma and chordoma. We first evaluated KB-0742 activity in sarcoma in a 300-immortalized cell line screen containing 18 soft tissue sarcoma cell lines. The median IC50 of the cell lines in the study was 0.8705 µM. Sarcoma cell lines were enriched for sensitivity to KB-0742 with 61% (11/18) of the lines with an IC50 below the median. The 11 cell lines had a median IC50 of 0.679 µM. We then evaluated the activity of KB-0742 in 5 patient-derived cell line (PDC) models, with all 5 showing a cytotoxic response to treatment as measured by negative GRmax values. Last, a single patient-derived organoid (PDO) model of adult rhabdomyosarcoma was evaluated. KB-0742 treatment resulted in an IC50 of 2.75 µM and a max inhibition rate of 98.61%. For chordoma we examined the activity of KB-0742 in vivo using 2 patient-derived xenograft (PDX) models. In model CF466, we observed a dose-dependent response with increased TGI and greater reductions in RNA polymerase II phosphorylation in tumors treated with KB-0742 at 60 mg/kg as compared to 30 mg/kg. We then evaluated KB-0742 as a single agent and in combination with afatinib in the model CF539. KB-0742 as a single agent showed similar TGI activity as afatinib, whereas the combination showed increased response as compared to the two single-agent arms. These data show that transcriptionally addicted tumors are sensitive to CDK9 inhibition via KB-0742 treatment, and support the continued development of our compound to potentially treat sarcoma and chordoma. KB-0742 is currently being evaluated in a phase 1/2 clinical trial (NCT04718675) for relapsed or refractory solid tumors or non-Hodgkin lymphoma. Once a recommended phase 2 dose is established, expansion cohorts for patients with sarcoma, chordoma, and other transcriptionally addicted tumors may be opened. Citation Format: Melinda A. Day, Douglas C. Saffran, Tressa Hood, Nikolaus Obholzer, Akanksha Pandey, Charles Y. Lin, Pavan Kumar, Daniel M. Freed, Jorge DiMartino. CDK9 inhibition via KB-0742 is a potential strategy to treat transcriptionally addicted cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2564." @default.
• W4282963013 created "2022-06-17" @default.
• W4282963013 creator A5000294837 @default.
• W4282963013 creator A5001258905 @default.
• W4282963013 creator A5015980689 @default.
• W4282963013 creator A5021709660 @default.
• W4282963013 creator A5022858974 @default.
• W4282963013 creator A5027680981 @default.
• W4282963013 creator A5032502969 @default.
• W4282963013 creator A5083416148 @default.
• W4282963013 creator A5091541605 @default.
• W4282963013 date "2022-06-15" @default.
• W4282963013 modified "2023-09-26" @default.
• W4282963013 title "Abstract 2564: CDK9 inhibition via KB-0742 is a potential strategy to treat transcriptionally addicted cancers" @default.
• W4282963013 doi "https://doi.org/10.1158/1538-7445.am2022-2564" @default.
• W4282963013 hasPublicationYear "2022" @default.
• W4282963013 type Work @default.
• W4282963013 citedByCount "2" @default.
• W4282963013 countsByYear W42829630132022 @default.
• W4282963013 countsByYear W42829630132023 @default.
• W4282963013 crossrefType "journal-article" @default.
• W4282963013 hasAuthorship W4282963013A5000294837 @default.
• W4282963013 hasAuthorship W4282963013A5001258905 @default.
• W4282963013 hasAuthorship W4282963013A5015980689 @default.
• W4282963013 hasAuthorship W4282963013A5021709660 @default.
• W4282963013 hasAuthorship W4282963013A5022858974 @default.
• W4282963013 hasAuthorship W4282963013A5027680981 @default.
• W4282963013 hasAuthorship W4282963013A5032502969 @default.
• W4282963013 hasAuthorship W4282963013A5083416148 @default.
• W4282963013 hasAuthorship W4282963013A5091541605 @default.
• W4282963013 hasConcept C104317684 @default.
• W4282963013 hasConcept C142724271 @default.
• W4282963013 hasConcept C153911025 @default.
• W4282963013 hasConcept C2778256501 @default.
• W4282963013 hasConcept C502942594 @default.
• W4282963013 hasConcept C54355233 @default.
• W4282963013 hasConcept C71924100 @default.
• W4282963013 hasConcept C81885089 @default.
• W4282963013 hasConcept C86339819 @default.
• W4282963013 hasConcept C86803240 @default.
• W4282963013 hasConceptScore W4282963013C104317684 @default.
• W4282963013 hasConceptScore W4282963013C142724271 @default.
• W4282963013 hasConceptScore W4282963013C153911025 @default.
• W4282963013 hasConceptScore W4282963013C2778256501 @default.
• W4282963013 hasConceptScore W4282963013C502942594 @default.
• W4282963013 hasConceptScore W4282963013C54355233 @default.
• W4282963013 hasConceptScore W4282963013C71924100 @default.
• W4282963013 hasConceptScore W4282963013C81885089 @default.
• W4282963013 hasConceptScore W4282963013C86339819 @default.
• W4282963013 hasConceptScore W4282963013C86803240 @default.
• W4282963013 hasIssue "12_Supplement" @default.
• W4282963013 hasLocation W42829630131 @default.
• W4282963013 hasOpenAccess W4282963013 @default.
• W4282963013 hasPrimaryLocation W42829630131 @default.
• W4282963013 hasRelatedWork W1975595193 @default.
• W4282963013 hasRelatedWork W2003523972 @default.
• W4282963013 hasRelatedWork W2057841153 @default.
• W4282963013 hasRelatedWork W2110646266 @default.
• W4282963013 hasRelatedWork W2939906752 @default.
• W4282963013 hasRelatedWork W4235120727 @default.
• W4282963013 hasRelatedWork W4254747857 @default.
• W4282963013 hasRelatedWork W4320300926 @default.
• W4282963013 hasRelatedWork W4361823356 @default.
• W4282963013 hasRelatedWork W4367397467 @default.
• W4282963013 hasVolume "82" @default.
• W4282963013 isParatext "false" @default.
• W4282963013 isRetracted "false" @default.
• W4282963013 workType "article" @default.